Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Kennedy

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Cell Reports|September 15, 2024
Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interactionMaximillian A Robinson, Alan Kennedy, Carolina T Orozco, et al.
Science Immunology|June 2, 2019
CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cellsVitalijs Ovcinnikovs, Ellen M Ross, Lina Petersone, et al.
NPJ Vaccines|May 2, 2026
High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodiesChloe Rees-Spear, Olivia Payne, Emma Touizer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Ecotoxicology (London, England)|March 17, 2012
Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?Richard D Handy, Nico van den Brink, Mark Chappell, et al.
Environmental Science. Nano|April 16, 2025
U. S. federal perspective on critical research issues in nanoEHSJanet Carter, Rhema Bjorkland, William K Boyes, et al.
The Journal of Allergy and Clinical Immunology|April 23, 2016
Hematopoietic stem cell transplantation for CTLA4 deficiencyMary A Slatter, Karin R Engelhardt, Lauri M Burroughs, et al.
Nature Communications|October 3, 2019
Framework engineering to produce dominant T cell receptors with enhanced antigen-specific functionSharyn Thomas, Fiyaz Mohammed, Rogier M Reijmers, et al.
Blood|February 5, 2017
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutationsTie Zheng Hou, Nisha Verma, Jennifer Wanders, et al.
Science Translational Medicine|October 26, 2022
Therapeutic gene editing of T cells to correct CTLA-4 insufficiencyThomas Andrew Fox, Benjamin Christopher Houghton, Lina Petersone, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Cell Reports|September 15, 2024
Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interactionMaximillian A Robinson, Alan Kennedy, Carolina T Orozco, et al.
Science Immunology|June 2, 2019
CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cellsVitalijs Ovcinnikovs, Ellen M Ross, Lina Petersone, et al.
NPJ Vaccines|May 2, 2026
High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodiesChloe Rees-Spear, Olivia Payne, Emma Touizer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Ecotoxicology (London, England)|March 17, 2012
Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?Richard D Handy, Nico van den Brink, Mark Chappell, et al.
Environmental Science. Nano|April 16, 2025
U. S. federal perspective on critical research issues in nanoEHSJanet Carter, Rhema Bjorkland, William K Boyes, et al.
The Journal of Allergy and Clinical Immunology|April 23, 2016
Hematopoietic stem cell transplantation for CTLA4 deficiencyMary A Slatter, Karin R Engelhardt, Lauri M Burroughs, et al.
Nature Communications|October 3, 2019
Framework engineering to produce dominant T cell receptors with enhanced antigen-specific functionSharyn Thomas, Fiyaz Mohammed, Rogier M Reijmers, et al.
Blood|February 5, 2017
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutationsTie Zheng Hou, Nisha Verma, Jennifer Wanders, et al.
Science Translational Medicine|October 26, 2022
Therapeutic gene editing of T cells to correct CTLA-4 insufficiencyThomas Andrew Fox, Benjamin Christopher Houghton, Lina Petersone, et al.
Pageof 10